Novo Nordisk said it had agreed to license a potential rival to its weight-loss drug Ozempic from a Chinese company. The ...

Novo Nordisk has signed an exclusive global licensing deal worth up to $2 billion for UBT251, a weight-loss drug developed by ...

Novo Nordisk secures global rights (excluding China) for UBT251 in a $2B+ deal with United Biotechnology, advancing obesity ...

Wegovy is also available through NovoCare Pharmacy, which directly ship all dose strengths at a cost of $499 per month for ...

Novo Nordisk A/S agreed to pay United Laboratories International Holdings as much as $2 billion for a next-generation obesity ...

Software giant SAP has overtaken Danish drugmaker Novo Nordisk to become Europe’s most valuable company, in the latest ...

Germany-based software company SAP became Europe's most valuable firm on Monday, surpassing Denmark's pharmaceutical company ...

Novo Nordisk agreed to pay up to $2 billion for the rights to a developmental weight-loss and obesity drug from Chinese pharmaceutical company the United Bio-Technology (Hengqin) Co., as it looks to ...

Zerodha’s Nithin Kamath sparks debate on Ozempic, Mounjaro & their game-changing impact on obesity, addiction & industries. Is India ready for this shift?

German software developer SAP unseated Danish weight-loss drug maker Novo Nordisk as Europe’s most-valuable public company.

Researchers have criticised the UK drug industry trade association’s decision to restore Novo Nordisk’s membership despite the company being subject to ongoing regulatory breaches during its two year ...